Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer

Peng Peng, Xiaoyan Qiang, Guoyu Li, Lin Li, Shumao Ni, Qi Yu, Laura Sourd, Elisabetta Marangoni, Chao Hu, Dong Wang, Di Wu, Frank Wu

Mol Cancer Ther (2023) 22 (2): 205–214.

https://doi.org/10.1158/1535-7163.MCT-22-0012

Published: 01 February 2023

View articletitled, Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer

Includes: Supplementary data

Journal Articles

Abstract P215: The MDM2 inhibitor milademetan induces synthetic lethality in GATA3 mutant, ER positive breast cancer

Vijaya G. Tirunagaru, Gaia Bianco, Charlotte K. Y. Ng, Elisabetta Marangoni, Salvatore Piscuoglio, François-Clément Bidard, Robert C. Doebele

Mol Cancer Ther (2021) 20 (12_Supplement): P215.

https://doi.org/10.1158/1535-7163.TARG-21-P215

Published: 01 December 2021

View articletitled, Abstract P215: The MDM2 inhibitor milademetan induces synthetic lethality in GATA3 mutant, ER positive breast cancer

Journal Articles

Chromatin Regulators as a Guide for Cancer Treatment Choice

Zachary A. Gurard-Levin, Laurence O.W. Wilson, Vera Pancaldi, Sophie Postel-Vinay, Fabricio G. Sousa, Cecile Reyes, Elisabetta Marangoni, David Gentien, Alfonso Valencia, Yves Pommier, Paul Cottu, Geneviève Almouzni

Mol Cancer Ther (2016) 15 (7): 1768–1777.

https://doi.org/10.1158/1535-7163.MCT-15-1008

Published: 05 July 2016

View articletitled, Chromatin Regulators as a Guide for Cancer Treatment Choice

Includes: Supplementary data

Journal Articles

AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo

Ricardo Ribas, Sunil Pancholi, Stephanie K. Guest, Elisabetta Marangoni, Qiong Gao, Aurélie Thuleau, Nikiana Simigdala, Urszula M. Polanska, Hayley Campbell, Aradhana Rani, Gianmaria Liccardi, Stephen Johnston, Barry R. Davies, Mitch Dowsett, Lesley-Ann Martin

Mol Cancer Ther (2015) 14 (9): 2035–2048.

https://doi.org/10.1158/1535-7163.MCT-15-0143

Published: 02 September 2015

View articletitled, AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo

Includes: Supplementary data

Journal Articles

Abstract A9: Establishment and characterization of residual breast cancer patient-derived xenografts resistant to neo-adjuvant therapy.

Elisabetta Marangoni, Dalila Labiod, Franck Assayag, Rania El Botty, Rana Hatem, Sophie Richon, Sophie Chateau-Joubert, Marine Carlus, Hélène Bonsang-Kitzis, Alice Pinheiro, Cécile Laurent, Ivan Bièche, Fabien Reyal

Mol Cancer Ther (2013) 12 (11_Supplement): A9.

https://doi.org/10.1158/1535-7163.TARG-13-A9

Published: 01 November 2013

View articletitled, Abstract A9: Establishment and characterization of residual breast cancer patient-derived xenografts resistant to neo-adjuvant therapy.

Journal Articles

Abstract A8: The EurOPDX consortium: Sharing patient tumor-derived xenografts for collaborative multicentric preclinical trials.

Mol Cancer Ther (2013) 12 (11_Supplement): A8.

https://doi.org/10.1158/1535-7163.TARG-13-A8

Published: 01 November 2013

View articletitled, Abstract A8: The EurOPDX consortium: Sharing patient tumor-derived xenografts for collaborative multicentric preclinical trials.

Journal Articles

Abstract C174: Establishment of luminal breast cancer patient-derived xenografts with acquired resistance to both hormonotherapy and everolimus.

Rania El Botty, Paul Cottu, Franck Assayag, Pierre de la Grange, David Gentien, Aurélie Thuleau, Sophie Vacher, Sophie Chateau-Joubert, Ivan Bièche, Elisabetta Marangoni

Mol Cancer Ther (2013) 12 (11_Supplement): C174.

https://doi.org/10.1158/1535-7163.TARG-13-C174

Published: 01 November 2013

View articletitled, Abstract C174: Establishment of luminal breast cancer patient-derived xenografts with acquired resistance to both hormonotherapy and everolimus.

Journal Articles

Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts

Angela Romanelli, Anderson Clark, Franck Assayag, Sophie Chateau-Joubert, Marie-France Poupon, Jean-Luc Servely, Jean-Jacques Fontaine, Xiaohong Liu, Edward Spooner, Samantha Goodstal, Patricia de Cremoux, Ivan Bièche, Didier Decaudin, Elisabetta Marangoni

Mol Cancer Ther (2012) 11 (12): 2693–2703.

https://doi.org/10.1158/1535-7163.MCT-12-0441-T

Published: 09 December 2012

View articletitled, Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts

Includes: Supplementary data

Journal Articles

Abstract B11: A panel of patient-derived xenografts for preclinical efficacy studies in various breast cancer molecular subtypes.

Olivier Deas, Stefano Cairo, Victorine Boissay, Aurore Gorse, Christophe Ginestier, Emmanuelle Charafe-Jaufret, Elisabetta Marangoni, Didier Decaudin, Marie-France Poupon, Jean-Gabriel Judde

Mol Cancer Ther (2011) 10 (11_Supplement): B11.

https://doi.org/10.1158/1535-7163.TARG-11-B11

Published: 12 November 2011

View articletitled, Abstract B11: A panel of patient-derived xenografts for preclinical efficacy studies in various breast cancer molecular subtypes.

Journal Articles

Abstract A27: Efficacy of estramustine + docetaxel in docetaxel‐resistant human prostate cancer xenograft: a preclinical model of docetaxel resistance reversion

Ahmed Dahmani, Ludmilla De Plater, Charlotte Guyader, Jean‐Jacques Fontaine, Aurélie Berniard, Franck Assayag, Philippe Beuzeboc, Elisabetta Marangoni, Fariba Némati, Marie‐France Poupon, Christophe Pasik, Stéphane Oudard, Didier Decaudin

Mol Cancer Ther (2009) 8 (12_Supplement): A27.

https://doi.org/10.1158/1535-7163.TARG-09-A27

Published: 10 December 2009

View articletitled, Abstract A27: Efficacy of estramustine + docetaxel in docetaxel‐resistant human prostate cancer xenograft: a preclinical model of docetaxel resistance reversion

Journal Articles

CD44-targeting inhibits tumor growth and prevents post-chemotherapy relapse in human breast cancer xenografts

Marie-France Poupon, Elisabetta Marangoni, Nicolas Lecomte, Florence Smadjia-Joffe, Gonzague DePinieux

Mol Cancer Ther (2007) 6 (11_Supplement): A93.

Published: 01 November 2007

View articletitled, CD44-targeting inhibits tumor growth and prevents post-chemotherapy relapse in human breast cancer xenografts

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer

Abstract P215: The MDM2 inhibitor milademetan induces synthetic lethality in GATA3 mutant, ER positive breast cancer

Chromatin Regulators as a Guide for Cancer Treatment Choice

AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo

Abstract A9: Establishment and characterization of residual breast cancer patient-derived xenografts resistant to neo-adjuvant therapy.

Abstract A8: The EurOPDX consortium: Sharing patient tumor-derived xenografts for collaborative multicentric preclinical trials.

Abstract C174: Establishment of luminal breast cancer patient-derived xenografts with acquired resistance to both hormonotherapy and everolimus.

Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts

Abstract B11: A panel of patient-derived xenografts for preclinical efficacy studies in various breast cancer molecular subtypes.

Abstract A27: Efficacy of estramustine + docetaxel in docetaxel‐resistant human prostate cancer xenograft: a preclinical model of docetaxel resistance reversion

CD44-targeting inhibits tumor growth and prevents post-chemotherapy relapse in human breast cancer xenografts

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only